GLPG3667 + itraconazole

GLPG3667 + itraconazole refers to the co-administration of GLPG3667, a selective, reversible, ATP-competitive tyrosine kinase 2 (TYK2) inhibitor developed for immune-mediated and inflammatory diseases, with itraconazole, an oral antifungal and a potent inhibitor of CYP3A4. This combination is studied specifically to assess the effect of itraconazole on the pharmacokinetics and safety of GLPG3667 in healthy volunteers, primarily for drug-drug interaction purposes. GLPG3667 is in development for conditions such as systemic lupus erythematosus and dermatomyositis, and acts by inhibiting cytokine signaling via TYK2, impacting pathways such as the interferon, IL-12/IL-23, and IL-10 families. Itraconazole is used here because of its established role as a strong CYP3A4 inhibitor, allowing assessment of potential metabolic interactions relevant to future clinical co-administration scenarios[1][5][6][7][8].

Other names

itraconazole